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original article

Clostridium difficile in the Intensive Care Unit:
Epidemiology, Costs, and Colonization Pressure
Steven J. Lawrence, MD, MSc; Laura A. Puzniak, PhD, MPH; Brooke N. Shadel, PhD, MPH;
Kathleen N. Gillespie, PhD; Marin H. Kollef, MD; Linda M. Mundy, MD

objective. To evaluate the epidemiology, outcomes, and importance of Clostridium difficile colonization pressure (CCP) as a risk factor
for C. difficile–associated disease (CDAD) acquisition in intensive care unit (ICU) patients.
design.
setting.
patients.
1999.

Secondary analysis of data from a 30-month retrospective cohort study.
A 19-bed medical ICU in a midwestern tertiary care referral center.
Consecutive sample of adult patients with a length of stay of 24 hours or more between July 1, 1997, and December 31,

results. Seventy-six (4%) of 1,872 patients were identified with CDAD; 40 (53%) acquired CDAD in the ICU, for an incidence of 3.2
cases per 1,000 patient-days. Antimicrobial therapy, enteral feeding, mechanical ventilation, vancomycin-resistant enterococci (VRE) colonization or infection, and CCP (5.5 vs 2.0 CDAD case-days of exposure for patients with acquired CDAD vs no CDAD; P p .001) were
associated with CDAD acquisition in the univariate analysis. Only VRE colonization or infection (45% of patients with acquired CDAD
vs 16% of patients without CDAD; adjusted odds ratio, 2.76 [95% confidence interval, 1.36-5.59]) and a CCP of more than 30 case-days
of exposure (20% with acquired CDAD vs 2% with no CDAD; adjusted odds ratio, 3.77 [95% confidence interval, 1.14-12.49]) remained
statistically significant in the multivariable analysis. Lengths of stay (6.1 vs 3.0 days; P ! .001 by univariate analysis) and ICU costs ($11,353
vs $6,028; P ! .001 by univariate analysis) were higher for patients with any CDAD than for patients with no CDAD.
conclusions. In this nonoutbreak setting, the CCP was an independent risk factor for acquisition of CDAD in the ICU at the upper
range of exposure duration. Having CDAD in the ICU was a marker of excess healthcare use.
Infect Control Hosp Epidemiol 2007; 28:123-130

Clostridium difficile–associated disease (CDAD) is a nosocomial diarrheal illness associated with significant morbidity,
excess healthcare costs, and prolonged hospital stay.1 In developed countries, CDAD severity and incidence have increased, with recent estimates of 0.9-8.4 cases per 1,000 admissions or discharges, corresponding to the spread of a
recently characterized hypervirulent strain of C. difficile.2-6
Despite the high concentration of at-risk patients in intensive
care units (ICUs), relatively little is known about the impact
of CDAD in these settings. Two ICU outbreaks of CDAD
have been described,7,8 and 3 other studies have reported
incidences of CDAD in the ICU of 0.4-100 cases per 1,000
patient-days per 1,000 admissions.2,9,10 One analysis of the
National Nosocomial Infections Surveillance database identified associations between CDAD and length of ICU stay,
medical device use, and admission during the winter; how-

ever, other exposure data were limited, and costs were not
assessed.2
For nosocomial infection, determination of the relative
roles of endogenous risk factors, which affect host susceptibility to infection, versus exogenous risk factors related to
increased pathogen exposure may aid in the design of targeted
prevention measures.11 Endogenous CDAD risk factors, such
as advanced age, underlying comorbidities, and receipt of
antimicrobial agents12-15 and gastric acid suppression therapy,16 alter the natural resistance to CDAD provided by the
gut’s microbial flora; however, many of these factors are not
readily modifiable. Conversely, exogenous CDAD risk factors
are related to exposure to C. difficile spores in the hospital
environment. Epidemiologic and molecular typing studies
have confirmed prolonged hospitalization, physical proximity
to a patient with CDAD, and medical device use to be ex-
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ogenous risk factors.2,17-21 Colonization pressure is a useful
epidemiologic marker of exogenous risks that quantifies susceptible patients’ pathogen exposure in terms of the number
of infectious contacts and the duration of exposure. Colonization pressure is an independent risk factor for acquisition
of other nosocomial pathogens in ICUs22-25; however, its role
in CDAD has not been determined. The objectives of this
study were to describe the epidemiology of CDAD in severely
ill patients, to evaluate C. difficile colonization pressure (CCP)
as a risk factor for CDAD acquisition in a contained area,
and to estimate the effect of CDAD on ICU outcomes.

me th ods
Study Design, Population, and Site
This study was a secondary analysis of a 30-month retrospective cohort study. All patients consecutively admitted to
the Barnes-Jewish Hospital adult medical ICU with a length
of stay of 24 hours or more between July 1, 1997, and December 31, 1999, were eligible for participation. Barnes-Jewish Hospital is a 1,287-bed midwestern tertiary care medical
center with a 19-bed medical ICU that consists of 2 suites
(with 10 and 9 private beds) separated by pass-through hallways and shared equipment rooms. For patients with multiple
ICU admissions, only the first admission was counted if admissions were separated by 30 days or more. Multiple admissions within a 30-day period were aggregated. The study
was approved by the Washington University Human Studies
Committee and the Saint Louis University Institutional Review Board.

for toxins A or B were considered to have prevalent CDAD.
Patients with subsequent positive stool samples collected
more than 14 days after the initial positive result were defined
as having a recurrent case of CDAD and were considered to
be nonsusceptible until 14 days after collection of the subsequent positive stool sample.
Antimicrobial and Infection Control Practices
During the first 18 months of this study, preferred empirical
gram-negative antimicrobial agents were cycled as described
elsewhere.25 For patients with CDAD, vancomycin-resistant
enterococci (VRE), methicillin-resistant Staphylococcus aureus, or multidrug-resistant gram-negative colonization or
infection, routine barrier precautions, which consisted of
donning gowns and gloves before entering the rooms and
removing gowns and gloves and performing hand hygiene
after leaving the rooms, were in place during the first 12
months and last 6 months of the study.23,25 During months
13-24, routine barrier precautions consisted of glove use only,
without gowns, as previously reported.23 All rooms were routinely cleaned by applying standard quaternary ammonium
salt solution to hard surfaces. Cleaning was performed by 2
dedicated housekeepers during the first 10 months of the
study and by 4 patient service representatives, who also performed patient-related duties, during the final 20 months of
the study. Rooms occupied by patients with CDAD did not
undergo enhanced cleaning.

Study Definitions
CDAD was defined as detection of C. difficile toxin A or B
in a clinical stool specimen, the collection of which was ordered by the treating ICU physician, by means of a cytotoxicity assay (Bartels). The daily CDAD point prevalence was
calculated as the sum of patients with CDAD who were in
the ICU during the 14-day period the disease was considered
transmissible.
The CCP was calculated for each patient as the sum of the
daily CDAD point prevalences for every day spent in the ICU
while susceptible. For determination of the CCP, the following
assumptions were made: (1) all patients with a positive result
of a toxin test had CDAD, (2) patients with CDAD were
infectious and contributed to the CCP for 14 days after the
day the initial positive stool sample was collected, (3) patients
with no CDAD were susceptible during their entire ICU stay,
and (4) patients who had CDAD were susceptible again 14
days after the initial positive stool sample.
Patients with stool specimens collected during the period
between 24 hours after ICU admission and 24 hours after
ICU discharge that tested positive for toxins A or B were
considered to have acquired CDAD. Patients with stool
samples collected during the period between 14 days before
and less than 24 hours after ICU admission that tested positive

figure 1. Frequency distribution of Clostridium difficile colonization pressure among patients hospitalized in the medical intensive care unit of a large midwestern tertiary care center, July 1997
through December 1999. CDAD, C. difficile–associated disease.
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table 1. Results of Univariate Analysis of Patient Characteristics to Determine Risk Factors for Clostridium
difficile–Associated Disease (CDAD) Acquisition in the Medical Intensive Care Unit (ICU) of a Large Midwestern Tertiary Care Center
Patient group

Characteristic
Age, mean y (range)
Female sex
Nonwhite race
APACHE II score, mean Ⳳ SD
Dedicated housekeeping
Gowns used for contact precautions
Duration of susceptibility, median ICU-days (range)b
Nosocomial exposure
Antimicrobial therapy, typeb
Anti–gram positive
Anti–gram negative
Antianaerobic
Antifungal
Gastric acid suppression therapyb
Mechanical ventilation
Enteral tube feeding
P. aeruginosa bacteremiab
MRSA bacteremiab
VRE colonization or infectionb

Prevalent
CDAD
(n p 36)

Acquired
CDAD
(n p 40)

No CDAD
(n p 1,796)

Pa

68.9 (34-93)
18 (50)
14 (39)
22.7 Ⳳ 5.4
12 (33)
19 (53)
0

58.7 (16-91)
17 (42)
12 (30)
23.4 Ⳳ 6.1
11 (28)
26 (65)
9.0 (2-58)

59.3 (16-95)
943 (52)
797 (44)
21.1 Ⳳ 7.5
622 (35)
1,123 (62)
4.0 (1-123)

.84
.21
.07
.06
.35
.75
!.001

31
29
25
9
25
20
14
0
8
12

(86)
(81)
(69)
(25)
(69)
(56)
(39)
(22)
(33)

40
39
32
17
38
34
26
4
5
18

(100)
(98)
(80)
(42)
(95)
(85)
(65)
(10)
(12)
(45)

1,518
1,522
935
327
1,525
991
533
31
169
281

(84)
(85)
(52)
(18)
(85)
(55)
(30)
(2)
(9)
(16)

.007
.02
!.001
!.001
.08
!.001
!.001
.006
.42
!.001

note. Data are no. (%) of patients, unless otherwise indicated. See Methods for definitions of prevalent CDAD and
acquired CDAD. APACHE, Acute Physiology and Chronic Health Evaluation; MRSA, methicillin-resistant Staphylococcus
aureus; P. aeruginosa, Pseudomonas aeruginosa; VRE, vancomycin-resistant enterococci.
a
P values for comparison of acquired CDAD versus no CDAD were calculated by means of the x2 or Fisher exact test
(for variables expressed as proportions), the Student t test (for variables expressed as means), or the Mann-Whitney U
test (for variables expressed as medians).
b
For patients with any CDAD, data were recorded before the first test positive for C. difficile toxin.

Data Collection
Clinical, laboratory, and cost data were obtained from hospital informatics and clinical databases and included demographic characteristics, nosocomial exposures, comorbid nosocomial pathogens, Acute Physiology and Chronic Health
Evaluation II (APACHE II) score, and antimicrobial exposures, which were classified into previously described categories on the basis of their activity against gut flora.26,27 As
part of an ongoing VRE surveillance program, all stool specimens collected for C. difficile toxin detection were screened
for VRE, and rectal swab specimens were obtained from all
patients to screen for VRE on ICU admission and weekly
until discharge.23,25
Outcomes
The CDAD incidence density was calculated as the number
of acquired cases of CDAD during the study period per 1,000
ICU patient-days of susceptibility. Lengths of stay were defined as days elapsed from admission until discharge or until
death if the patient died. Total hospital costs were obtained
from the hospital’s financial accounting system and converted

to 2002 US dollars.28 The ICU costs were estimated by dividing total hospital costs by the length of hospital stay and
multiplying the dividend by the length of ICU stay.
Statistical Analysis
All patients in the cohort were used in the calculation of the
daily point prevalence of CDAD, but prevalent CDAD cases
were excluded for the risk factor analysis. For all univariate
analyses, categorical variables were compared using the x2
test or the Fisher exact test, and continuous variables were
compared by the Student t test or the Mann-Whitney U test
if nonnormally distributed. Logistic regression models were
used to evaluate risk factors for the dependent variables of
CDAD acquisition and ICU mortality (ie, death from any
cause while in the ICU). Age, sex, and exposure variables
with a univariate P value of less than .10 for the association
with CDAD acquisition or mortality were selected for the
regression models. Because of the unusual frequency distribution of the CCP (Figure 1), multiple dichotomous variables
were created (categories of 0 [reference], 1-3, 4-7, 8-14, 1530, and more than 30 case-days of exposure) in the CDAD
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figure 2. Daily point prevalence of Clostridium difficile–associated disease (CDAD) and infection control practices in the medical
intensive care unit of a large midwestern tertiary care center, July 1997 through December 1999.

acquisition regression model. To further examine CCP as a
risk factor for CDAD acquisition, successive regression models were created by varying the hypothetical cutoff values for
CCP. Starting with the observed median used in the original
model, the binary CCP was increased successively. Multiple
linear regression was used to evaluate the association of
CDAD with ICU costs and ICU lengths of stay, using logtransformed dependent variables and the same independent
variable selection method used for the mortality logistic regression model. Regression diagnostic analyses were performed to identify outliers. A 2-tailed P value of less than
.05 was considered to be statistically significant. All analyses
were performed using SPSS statistical software, version 12.0
for Windows (SPSS).

days (range, 2-58 days). The pattern of CDAD appearance
was sporadic, reflecting intermittent introductions by patients
with prevalent cases and onset of acquired cases. The highest
CDAD daily point prevalence was 4 cases, which occurred
on 5 consecutive days (Figure 2). On 517 days (57% of the
study period), the CDAD point prevalence was 0 cases.
Twenty (56%) of the 36 prevalent cases were introduced into
the ICU on one of those days. Nine (22%) of the 40 acquired
cases occurred within 14 days of one of these CDAD introductions. Twenty-three acquired cases (58%) occurred on a
day when the CDAD point prevalence was 0 cases. Two patients developed recurrent episodes.

res ults

Patients who acquired CDAD were demographically similar
to those with no CDAD (Table 1). Antimicrobial use was
widespread, with 1,653 cohort patients (88%) receiving at
least 1 agent during their ICU stay. Receipt of antimicrobial
agents from any class, number of susceptible days spent in
the ICU, mechanical ventilation, enteral feeding, VRE colonization or infection, and Pseudomonas aeruginosa bacteremia
were associated with CDAD acquisition in the univariate analysis. Gown use and housekeeping practices were similar for
patients with acquired CDAD and those without CDAD.
Other than the CCP, only VRE colonization or infection was
associated with CDAD acquisition, after adjusting for confounders (adjusted odds ratio [aOR], 2.76 [95% confidence
interval (CI), 1.36-5.59]).

Cohort Description
During the 30-month study period, 2,631 patients were
treated in the ICU; 748 (28%) were excluded because their
ICU stay was less than 24 hours, and 11 (0.4%) were excluded
because data were missing, leaving 1,872 evaluable cohort
patients. The mean age was 59.5 years, 978 (52%) were
women, 1,813 (97%) were white or African American, and
the mean APACHE II score was 21.1.
Epidemiology of CDAD
Seventy-six patients (4%) had confirmed CDAD, based on
positive results of toxin tests during their ICU stay (Table 1).
Thirty-six (47%) of these patients had prevalent CDAD on
ICU entry, whereas 40 (53%) had acquired CDAD, for an
incidence density of 3.2 cases per 1,000 patient-days. The
median duration spent in the ICU before acquisition was 9.0

Risk Factor Analysis

CCP
The median CCP experienced by each patient in the cohort
was 2.0 CDAD case-days of exposure (range, 0-109 case-days;

cdad acquisition by patients in the icu
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table 2. Results of Univariate and Multivariate Analyses of Clostridium difficile Colonization Pressure (CCP) as a Risk Factor for C. difficile–Associated Disease (CDAD) Acquisition in the Medical Intensive Care Unit of a Large Midwestern Tertiary Care Center
Patient group
Risk factor
Univariate analysis only
CCP, median (range)
Logistic regression model
CCP 10
CCP 12
CCP 14
CCP 19
CCP 110

Acquired CDAD
(n p 40)

No CDAD
(n p 1,796)

Adjusted OR
(95% CI)

5.5 (0-103)

2.0 (0-109)

…

28
27
21
15
15

(70)
(68)
(52)
(38)
(38)

1,031
808
505
207
177

(57)
(45)
(28)
(12)
(10)

0.88
1.27
1.39
1.81
2.17

(0.42-1.85)
(0.61-2.64)
(0.69-2.80)
(0.86-3.78)
(1.04-4.56)

Pa
.001
.11
.005
.001
!.001
! .001

note. Data are no. (%) of patients, unless otherwise indicated. The CCP was calculated for each
patient as the sum of the daily CDAD point prevalences for every day spent in the ICU while susceptible.
Multiple dichotomous variables were created for the CCP because of its unusual frequency distribution.
See Methods for additional assumptions made in determining the CCP. CI, confidence interval; OR,
odds ratio.
a
P values are for univariate analyses calculated by the Mann-Whitney U test (for median CCP) or
the x2 test (for categorized CCP variables).

Figure 1). Notably, 808 patients (43%) experienced no CCP
and had a shorter median ICU length of stay than patients
who experienced any CCP (2.5 vs 4.0 days; P ! .001). Five
patients acquired CDAD less than 24 hours after ICU discharge. The remaining 71 patients with CDAD contributed
555 case-days of risk to the CCP (median, 6.0 case-days;
range, 1-33 case-days). The median CCP for all 40 patients
who acquired CDAD was 5.5 case-days of exposure (range,
0-103 case-days); however, 12 (30%) experienced no CCP
while in the ICU. The remaining 28 patients experienced a
median CCP of 13.0 case-days. In univariate analysis, the
CCP was associated with acquiring CDAD (median CCP, 5.5
case-days for acquired CDAD vs 2.0 case-days for no CDAD;
P p .001) (Table 2). In the logistic regression model that
evaluated risk factors for CDAD acquisition, other than VRE
colonization or infection, only the highest category of CCP
(ie, more than 30 case-days of exposure) was significant (20%
for acquired CDAD vs 2% for no CDAD; aOR, 3.77 [95%
CI, 1.14-12.49]) (Figure 3). With sequential logistic regression
modeling, a threshold CCP of 10 was necessary for CCP to
become an independent risk factor for CDAD acquisition
(aOR, 2.17 [95% CI, 1.04-4.56]) (Table 2). Acquisition of
CDAD occurred in 15 (8%) of the 192 susceptible patients
who experienced more than 10 case-days of CCP and in only
25 (2%) of 1,619 susceptible patients with a CCP of 10 casedays or less.

patients for whom cost data were available. Although mortality was not significantly different, lengths of hospital and
ICU stay were approximately twice as long for patients with
any CDAD, compared with patients without CDAD. Hospital
and ICU costs were similarly higher for patients with any
CDAD, compared with patients without CDAD. Having any
CDAD was also associated with discharge to a long-term care
facility. The increased costs and lengths of stay were even
more pronounced for patients who acquired CDAD while in
the ICU. In the logistic regression model, APACHE II score,
nonwhite race, methicillin-resistant S. aureus bacteremia,
VRE colonization or infection, enteral feeding, mechanical
ventilation, and receipt of an antifungal agent were independently associated with ICU mortality, although CDAD was
not. By multivariable linear regression modeling to adjust for
confounding, having any CDAD was significantly associated

Impact of CDAD on Outcomes and Costs
Outcomes for patients with any CDAD, acquired CDAD only,
and no CDAD are presented in Table 3. In total, 378 patients
(20%) died in the ICU, and 308 (16%) required transfer to
a long-term care facility. The median length of ICU stay was
3.0 days, and the median ICU costs were $6,137 for the 1,835

figure 3. Risk of Clostridium difficile–associated disease (CDAD)
acquisition in the medical intensive care unit of a large midwestern
tertiary care center, according to C. difficile colonization pressure
(CCP) category, July 1997 through December 1999.
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table 3. Outcomes and Costs for Patients in the Medical Intensive Care Unit (ICU) of a Large Midwestern Tertiary
Care Center, Stratified by Clostridium difficile– Associated Disease (CDAD) Status
Patient group
Variable
Mortality
During ICU stay
During non-ICU hospital stay
Discharge to long-term care facility
Length of stay, median d (range)
ICU
Hospital
Costs, median $US (range)b
During ICU stay
During entire hospital stay

Any CDAD
(n p 76)

Acquired CDAD only
(n p 40)

No CDAD
(n p 1,796)

Pa

15 (20)
27 (36)
21 (28)

7 (18)
13 (32)
9 (22)

363 (20)
495 (28)
287 (16)

.92
.13
.007

6.1 (1-86)
24.5 (2-184)

14.9 (1-86)
38.3 (4-184)

3.0 (1-106)
10.1 (1-397)

!.001
!.001

11,353 (2,061-175,878)
45,910 (5,936-271,024)

25,092 (2,497-175,878)
68,036 (7,991-271,024)

6,028 (987-255,941)
18,620 (1,668-334,523)

!.001
!.001

note.

Data are no. (%) of patients, unless otherwise indicated. See Methods for the definition of acquired CDAD.
P values for univariate comparison between patients with any CDAD and patients with no CDAD were calculated by the x2 test (for
variables expressed as proportions) or the Mann-Whitney U test (for variables expressed as median values).
b
Cost data were available for 1,835 patients: 75 had any CDAD, 39 had acquired CDAD only, and 1,760 had no CDAD.
a

with a greater length of ICU stay (aOR, 1.24 [95% CI, 1.071.44]) and trended toward higher ICU costs (aOR, 1.18 [95%
CI, 0.995-1.39]). In both of these models, the following variables were also associated with increased ICU costs and
lengths of ICU stay: age; APACHE II score; receipt of antimicrobials with activity against gram-negative, anaerobic, or
fungal organisms; concomitant nosocomial bacteremia; VRE
colonization; enteral feeding; and mechanical ventilation.

dis c us s i on
The results of this large cohort study confirmed CDAD to
be a sporadic ICU nosocomial infection in the absence of a
recognized outbreak, with an observed incidence similar to
that reported elsewhere for ICUs at large teaching hospitals.2
As others have reported in ICU and non-ICU populations,
we observed an association between CDAD and markedly
increased lengths of stay2 and a subsequent trend toward
higher costs,1 particularly for patients who acquired CDAD
in the ICU. Many nosocomial infections have been reported to be markers of increased use of ICU resources,29-31 and
our findings suggest that CDAD is another important ICU
infection.
Efforts to prevent CDAD in vulnerable ICU patients are
now more imperative than ever, because a C. difficile strain
with enhanced virulence has recently emerged in North
America and Europe. This strain, characterized by the presence of a binary toxin, hyperproduction of toxins A and B,
and universal resistance to fluoroquinolones, has caused multiple severe CDAD outbreaks with higher attributable mortality.3-5 A number of molecular epidemiology studies have
previously confirmed that exogenous transmission of C. difficile from other patients and contaminated hospital environments occurs but is not necessarily sufficient for the development of CDAD.12,18,19,32-34 After exposure, endogenous

risk factors that affect the normal colonic flora or the host
immune response probably determine whether CDAD will
develop or whether asymptomatic, and possibly protective,
colonization occurs.12,14,21,35 Prevention strategies usually consist of reducing exogenous risk with barrier infection control
policies and bleach disinfection or of reducing endogenous
risk through restrictions on the use of high-risk antimicrobials.36-39
Although our findings provide further evidence that CDAD
transmission probably occurs indirectly between patients in
close proximity,19 they also suggest that endogenous risk factors may be the more important targets for prevention when
the incidence of CDAD is sporadic. First, most acquired
CDAD cases occurred when there was no detectable CDAD
in the ICU. Second, most imported cases were not temporally
associated with subsequent acquired cases. Third, unlike with
VRE, the infection control policy of donning gowns with
gloves in this same cohort was not associated with a reduced
risk of CDAD acquisition, compared with a gloves-only policy.23 Perhaps most importantly, overall exposure to C. difficile
experienced by susceptible patients, as quantified by the CCP,
was an independent risk factor for CDAD only when the
duration of exposure exceeded 10 case-days. Indeed, nearly
one third of patients with acquired CDAD experienced no
CCP before CDAD onset.
Thus, in a setting of sporadic CDAD incidence, it seems
prudent to focus on mitigation of modifiable endogenous
risk factors by emphasizing judicious use of antimicrobial
agents and gastric acid suppression agents. Although it is
often not feasible to restrict use of these drugs in critically
ill patients, when treatment with broad-spectrum antimicrobial agents is necessary, substituting cephalosporins and fluoroquinolones with potentially lower-risk drugs, such as piperacillin-tazobactam, may be preferable.40,41 Our findings

cdad acquisition by patients in the icu

suggest that use of gloves alone may be equivalent to concomitant use of gloves and gowns for preventing transmission; however, this hypothesis would need to be formally
tested before changes in barrier infection control guidelines
can be recommended. Furthermore, intensive environmental
disinfection with sodium hypochlorite should be considered
early in a suspected CDAD outbreak.37,42 Prospective molecular epidemiology studies are needed to confirm the efficacy
of such a prevention strategy.
To our knowledge, we describe the first large-scale study
that investigated the epidemiology of CDAD in an ICU setting
and the first study that evaluated colonization pressure as a
risk factor for CDAD acquisition. Strengths of this study include a well-characterized cohort, availability of thorough
outcomes data, and a multiyear duration to minimize the
effect of minor spikes or decreases in CDAD incidence.
As with most observational investigations, our study has
several limitations. First, our model for calculating the CCP
was based on the assumptions that (1) the onset of diarrhea
occurred rapidly after exposure to C. difficile in critically ill
patients, (2) patients with CDAD shed epidemiologically significant amounts of C. difficile in their stools for 14 days after
diagnosis, and (3) patients without laboratory-confirmed C.
difficile toxin are not at risk to transmit C. difficile. Use of a
different cutoff time for distinguishing prevalent from acquired CDAD (eg, 48 hours instead of 24 hours) would have
had little impact on our estimates, because the number of
acquired cases that occurred 24-48 hours after ICU admission
was similar to the number that occurred 24-48 hours after
discharge. Although it is known that asymptomatic inpatients
are frequently colonized with C. difficile,14,21 their importance
as reservoirs is not clear. Second, the model was unable to
account for the CCP experienced in the hospital before ICU
admission. Third, it is possible that some of the patients with
a positive result of a C. difficile toxin test did not have CDAD;
however, this misclassification bias was likely to be infrequent,
given the high specificity of the cytotoxicity assay and because
stool toxin tests were not routinely ordered unless clinically
compatible symptoms were present. Fourth, because this
study was a secondary analysis, the primary data on specific
drugs or drug classes were not available to more completely
characterize antimicrobial exposure. In addition, direct ICUspecific cost data were unavailable and were likely underestimated by our method. Although we observed associations
between CDAD and increased lengths of ICU stay and costs,
we cannot conclude that these increases are attributable solely
to CDAD. Indeed, our multivariable analyses suggest that
many of the measured exposure variables were associated with
these complex outcomes. Our hypothesis is that having
CDAD in the ICU is one of many markers for increased use
of healthcare resources. Finally, the reported data predated
the emergence of the recently recognized hypervirulent strain,
which may exhibit transmission dynamics that differ from
those of the strains recovered from patients in our study.
CDAD is an important ICU infection and has considerable
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implications for resource use. Colonization pressure becomes
an important exogenous risk factor for CDAD transmission
only at high levels of exposure. In addition to use of traditional barrier infection control methods, mitigation of endogenous risk factors should be emphasized.
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